ClinicalTrials.gg
Active, not recruitingNCT06336291GLIOSTELLAUpdated Apr 21, 2026

A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence

A Phase 2 interventional study of L19TNF and L19TNF in Glioblastoma, sponsored by Philogen S.p.A.. Active, not recruiting at 9 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-21.

Sponsored by Philogen S.p.A. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 1,302 studies in Glioblastoma with a site in United States — 194 open to participants now, 324 under way, 16 of them phase 3. Glioblastoma · United States.

Planned enrollment
182nd of 1,155
90 · median 33
Started
2024
with 42 others
Phase 2
396 of 1,302
37 open now
Primary completion
2026-06
later than 60 of 322 live
Registered
1,180th of 1,302
by date

Among the 1,302 studies in Glioblastoma with a site in United States, this one is the 182nd largest by planned enrollment of the 1,155 interventional ones that give a count, is one of 43 that started in 2024, is one of 396 in phase 2, reaches primary completion later than 60 of the 322 other live ones, and was the 1,180th registered.

Glioblastoma

2,135 studies on the registry are indexed under Glioblastoma; 467 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

194 of the 1,302 studies in Glioblastoma with a site in United States are open now. Recruiting first, the newest first:

189 more — sign in →

All 194 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 339 Glioblastoma studies recruiting now, 234 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,302 studies in Glioblastoma with a site in United States, or all of them as a file.
02

Study summary

The trial aims to collect safety, efficacy, exposure, dose- response, pharmacokinetic and pharmacodynamic information of the combination of L19TNF and lomustine at different dose levels in patients with Glioblastoma at progression or recurrence

Read the detailed description

The present study is a randomized, open-label, non-controlled phase II study in patients with glioblastoma at any progression/recurrence (first and later).

Overall, 90 subjects will be enrolled and parallel assigned in a 1:1 fashion to one of six treatment arms (from A to F) of 15 patients each.

Each arm has a different combination of L19TNF (7 μg/kg or 10 μg/kg or 13 μg/kg) and lomustine at different dose levels (90 or 110 mg/m2).

Treatment is based on a 42-day cycle for up to a maximum of 6 cycles.

This is an open-label study, so there is no blinding.

Patients who successfully complete the screening evaluations and are eligible for participation in the study will be enrolled and randomly assigned (1:1:1:1:1:1) to either of the six parallel treatment arms.

To maintain an appropriate balance between the six treatment arms and avoid undesired confounding effect of different factors, patients will be randomized in accordance with the following strata:

  • MGMT status
  • Steroid administration
  • Previous systemic therapy treatment for progression

A randomization list will be prepared for each stratum using permuted block, the block sizes will be chosen randomly from different, pre-specified sizes with an equal treatment allocation ratio. The labels for the arms are assigned randomly within each block (fixed seed). The obtained final list is sorted by block together with the progressive enrollment number for the patients.

The primary objective of this study is to select the optimal regimen of L19TNF in combination with lomustine, that maximizes effects on clinical parameters and minimizes the probability of moderate to severe adverse events, among six (three L19TNF doses x two lomustine doses) combination schedules for the treatment of patient with progressing or recurrent glioblastoma.

Primary endpoints include Safety (Incidence of adverse Events (AEs), Serious Adverse Events (SAEs) and Drug-Induced Liver Injury (DILI), standard laboratory assessments, ECG, ECHO and physical examination according to CTCAE v.5.0) and Efficacy (Survival rate at 12 months).

The secondary objective of this study is to further evaluate safety, efficacy, exposure, dose-response, pharmacokinetic and pharmacodynamic information of the combination of L19TNF and lomustine at different dose levels to determine the best dose regimen for further studies.

During the conduct of the study the safety information collected will be routinely reviewed by the Data and Safety Monitoring Board (DSMB) in order to identify possible safety concerns.

If the probability in a treatment arm that the development of unacceptable toxicity rate exceeds 33 % is equal or higher than 80%, the recruitment to this treatment arm will be interrupted and the DSMB will be informed to assess the events and relationship to the study treatment. The DSMB may then recommend to re-start recruitment again for the treatment arm or permanently suspend it.

In case of a treatment-related death, recruitment will be suspended for all treatment arms until the Data and Safety Monitoring Board (DSMB) has reviewed the event and recommended to restart

03

Conditions studied

  • Glioblastoma

Browse trials for

Keywords

  • L19TNF
  • Glioblastoma at progression
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, age ≥18.
  2. Patients with confirmed glioblastoma per 2021 WHO classification progression according to RANO criteria.
  3. For operated patients, the histological report must document glioblastoma recurrence and a new MRI will need to be done at 3-5 weeks after surgery (directly before study treatment start). Study treatment will need to start minimum 4 weeks after surgery.
  4. MGMT promotor status known.
  5. Performance Status (KPS) ≥ 60%.
  6. Documented negative test for --. For HBV serology, the determination of HbsAg and anti-HbcAg Ab is required. In patients with serology documenting previous exposure to HBV, negative serum HBV-DNA is required (HBV-DNA is not required for patients with documented vaccination report). For HCV, HCV-RNA or HCV antibody test is required. Subjects with a positive test for HCV antibody but no detection of HCV-RNA indicating no current infection are eligible.
  7. Female patients: female patients must be either documented not Women Of (WOCBP)* or must have a negative pregnancy test within 14 days of starting treatment.

    Additionally WOCBP must agree to use, from the screening to 6 months following the last study drug administration, highly effective methods, as defined by the "Recommendations for contraception and pregnancy testing in clinical trials" issued by the Head of Medicine Agencies' Clinical Trial Facilitation Group (www.hma.eu/ctfg.html) and which include, for instance, progesterone-only or combined (estrogen- and progesterone-containing) hormonal contraception associated with inhibition of ovulation, intrauterine devices, intrauterine hormone-releasing systems, bilateral tubal occlusion or vasectomized partner.

  8. Male patients: male subjects able to father children must agree to use two acceptable methods of contraception throughout the study and until 6 months after last study drug administration (e.g. condom with spermicidal gel). Double-barrier contraception is required.
  9. Personally signed and dated document indicating that the subject has been informed of all pertinent aspects of the study.
  10. Willingness and ability to comply with the scheduled visits, treatment plan, laboratory tests and other study procedures.

    • Women of childbearing potential (WOCBP) are defined as females who have experienced menarche, are not (12 months with no menses without an alternative medical cause) and are not permanently sterilized (e.g., tubal occlusion, hysterectomy, bilateral oophorectomy, or bilateral salpingectomy).

Exclusion criteria

Exclusion Criteria:

  1. Inability to undergo contrast-enhanced MRI.
  2. Anti-cancer treatment with radiation therapy, chemotherapy, targeted therapies, immunotherapy, hormones, tumor treating fields or other antitumor therapies within 4 weeks prior to study treatment start.
  3. Subjects who participated in an drug or device study within 4 weeks prior to study treatment start.
  4. Grade ≥ 4 myelotoxicity with previous treatment of alkylating agents (e.g., TMZ, CCNU).
  5. Previous treatment with Bevacizumab.
  6. Previous treatment with L19TNF.
  7. Previous treatment in the PH-L19TNFCCNU-02/20 study.
  8. Known history of allergy to TNF, any in the study medication or any other intravenously administered human proteins/peptides/antibodies.
  9. (ANC) \< 1.5 x 10\^9/L; \< 100 x 10\^9/L or (Hb) \< 9.0 g/dl.
  10. Chronically impaired renal function as indicated by \< 60 mL/min/1.73m2 or for patients older than 65 years without albuminuria or proteinuria, creatinine clearance \< 45 mL/min/1.73m2.
  11. Inadequate liver function (, AST, ALP ≥ 2.5 x or total ≥ 1.5 x ULN).
  12. > 1.5 ULN.
  13. Any severe concomitant condition which makes it undesirable for the patient to participate in the study or which could jeopardize compliance with the protocol, in the opinion of the investigator.
  14. Active or history of disease that might deteriorate when receiving an immune-stimulatory agent, in the judgement of the investigator.
  15. History within the last year of cerebrovascular disease and/or acute or subacute coronary syndromes including myocardial infarction, unstable or severe stable angina pectoris.
  16. Heart insufficiency (> Grade II, (NYHA) criteria).
  17. cardiac arrhythmias or requiring permanent medication.
  18. \<55% or any other abnormalities observed during baseline and echocardiogram investigations that are considered as clinically significant by the investigator. Patients with a marked prolongation of /QTc interval (e.g., repeated demonstration of QTc >470 milliseconds using Fredricia's QT correction formula) are excluded.
  19. Uncontrolled hypertension.
  20. Known arterial aneurism at high risk of rupture.
  21. Ischemic peripheral vascular disease (Grade IIb-IV according to Leriche-Fontaine classification)
  22. Anxiety ≥ Grade 3.
  23. Severe diabetic retinopathy such as severe non-proliferative retinopathy and proliferative retinopathy.
  24. Major trauma including major surgery (such as abdominal/cardiac/thoracic surgery) within 3 weeks of administration of study treatment.
  25. Known active or latent tuberculosis (TB).
  26. Pregnancy or breast feeding.
  27. Requirement of chronic administration of high dose or other drugs. Subjects must have been either off corticosteroids, or on a stable or decreasing dose ≤ 4 mg daily dexamethasone (or equivalent) for 7 days prior to start of treatment. Limited or occasional use of corticosteroids to treat or prevent acute adverse reactions is not considered an exclusion criterion.
  28. Presence of active and uncontrolled infections or other severe concurrent disease, which, in the opinion of the investigator, would place the patient at undue risk or interfere with the study.
  29. Concurrent unless the patient has been disease-free without intervention for at least 2 years.
  30. Growth factors or immunomodulatory agents within 7 days prior to the administration of study treatment.
  31. Serious, non-healing wound, ulcer, or bone fracture.
  32. Deep vein thrombosis, pulmonary embolism or other acute vascular events within 6 months.
  33. Anticoagulation therapy with P2Y12 antagonists (e.g., clopidogrel, ticagrelor) and vitamin K antagonists (e.g., phenprocoumon, warfarin).
  34. Requirement of concurrent use of other anti-cancer treatments or agents other than study medication.
  35. Any recent within 4 weeks prior to treatment or plan to receive live vaccination during the study.
Terms in these criteria, in plain language(30)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Arm A

    Patients will be treated with L19TNF on Days 1, 3 and 5, and on Days 22, 24 and 26 and Lomustine on Day 1 (in the evening after L19TNF infusion) of a 42-day cycle for up to a maximum of 6 cycles.

    Drug: L19TNF · Drug: Lomustine

  • Experimental
    Arm B

    Patients will be treated with on Days 1, 3 and 5, and on Days 22, 24 and 26 and Lomustine on Day 1 (in the evening after L19TNF infusion) of a 42-day cycle for up to a maximum of 6 cycles

    Drug: L19TNF · Drug: Lomustine

  • Experimental
    Arm C

    Patients will be treated with L19TNF on Days 1, 3 and 5, and on Days 22, 24 and 26 and Lomustine on Day 1 (in the evening after L19TNF infusion) of a 42-day cycle for up to a maximum of 6 cycles.

    Drug: L19TNF · Drug: Lomustine

  • Experimental
    Arm D

    Patients will be treated with L19TNF on Days 1, 3 and 5, and on Days 22, 24 and 26 and Lomustine on Day 1 (in the evening after L19TNF infusion) of a 42-day cycle for up to a maximum of 6 cycles.

    Drug: L19TNF · Drug: Lomustine

  • Experimental
    Arm E

    Patients will be treated with L19TNF on Days 1, 3 and 5, and on Days 22, 24 and 26 and Lomustine on Day 1 (in the evening after L19TNF infusion) of a 42-day cycle for up to a maximum of 6 cycles.

    Drug: L19TNF · Drug: Lomustine

  • Experimental
    Arm F

    Patients will be treated with L19TNF on Days 1, 3 and 5, and on Days 22, 24 and 26 and Lomustine on Day 1 (in the evening after L19TNF infusion) of a 42-day cycle for up to a maximum of 6 cycles.

    Drug: L19TNF · Drug: Lomustine

Interventions

  • DrugL19TNF

    7 μg/kg

    Also known as: onfekafusp alfa

  • DrugL19TNF

    10 μg/kg

    Also known as: onfekafusp alfa

  • DrugL19TNF

    13 μg/kg

    Also known as: onfekafusp alfa

  • 90 mg/m2

  • 110 mg/m2

06

What researchers measure

Primary outcomes

  1. Adverse Events

    Occurence of AEs according to CTCAE v.5.0

    Time frame: From the screening, throughout the study, until demonstration of confirmed disease progression, treatment begins with another anti-cancer agent or surgery, or for a minimum of 12 months

  2. Serious Adverse Events

    Occurence of SAEs according to CTCAE v.5.0

    Time frame: From the screening, throughout the study, until demonstration of confirmed disease progression, treatment begins with another anti-cancer agent or surgery, or for a minimum of 12 months

  3. Unacceptable Toxicity

    Occurence of Unacceptable Toxicity according to CTCAE v.5.0

    Time frame: From the start of treatment up to 3 months

  4. DILI assessment

    Occurence of DILI according to CTCAE v.5.0

    Time frame: From the screening, throughout the study, until demonstration of confirmed disease progression, treatment begins with another anti-cancer agent or surgery, or for a minimum of 12 months

  5. Survival

    Survival rate at 12 months

    Time frame: From enrollment to death from any cause, for a minimum of 12 months

Secondary outcomes

  1. Overall Survival

    Time frame: From enrollment to death from any cause, for a minimum of 12 months

  2. Progression Free Survival

    Time frame: From enrollment to the date of progression or death from any cause, whichever came first, for a minimum of 12 months

  3. Objective Response Rate

    The rate of patients achieving Complete Response (CR) or Partial Response (PR) defined according to RANO criteria

    Time frame: From enrollment to death from any cause, for a minimum of 12 months

  4. Disease Control Rate

    The rate of patients achieving complete (CR), partial (PR) and stable response (SD)

    Time frame: From enrollment to death from any cause, for a minimum of 12 months

  5. Duration of Response

    Time frame: From enrollment to the date of progression or death from any cause, whichever came first, for a minimum of 12 months

  6. Time to reach maximum drug concentration [Tmax]

    Pharmacokinetics assessment of L19TNF through blood sampling

    Time frame: From the start of treatment up to 9 months

  7. Terminal half-life [t1/2]

    Pharmacokinetics assessment of L19TNF through blood sampling

    Time frame: From the start of treatment up to 9 months

  8. Area under the drug concentration-time curve, extrapolated to infinity [AUC]

    Pharmacokinetics assessment of L19TNF through blood sampling

    Time frame: From the start of treatment up to 9 months

  9. Maximum drug concentration [Cmax]

    Pharmacokinetics assessment of L19TNF through blood sampling

    Time frame: From the start of treatment up to 9 months

  10. Human anti-fusion protein antibodies (HAFA) levels against L19TNF

    Determination of the formation of Human Anti-Fusion protein Antibodies (HAFA) against L19TNF

    Time frame: From the start of treatment to the date of progression or death for any cause, whichever come first

07

Study locations

9 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Jun 2026, 25 months after the start.

Of 51 industry-sponsored phase 2 interventional studies under Glioblastoma, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 58. This study's planned 25 months is below that.

Counting every sponsor, half of 249 studies reached it within 56 months; a quarter within 40 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2024
First posted
Mar 28, 2024
StartActual
May 22, 2024
Primary completionEst.
Jun 2026
CompletionEst.
Jun 2026
Last update
Apr 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06336291
Lead sponsor
Philogen S.p.A.
Responsible party
Sponsor
First posted
Mar 28, 2024
Start date
May 22, 2024
Primary completion
Jun 2026 (estimated)
Completion
Jun 2026 (estimated)
Last update
Apr 21, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Onfekafusp alfa

Start the discussion